BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Syntarga BV Announces Additional Antibody-Drug Conjugate Collaborations


6/1/2010 12:42:17 PM

Nijmegen, The Netherlands – May 31, 2010 – Syntarga B.V., the emerging Antibody- Drug Conjugate (ADC) company, announces today that it entered into three additional research collaborations since its March 2010 press release. These latest agreements comprise a second collaboration with one of the two top-15 biopharma companies announced in March and collaborations with a new, undisclosed top-tier biopharma company, and a new, undisclosed mid-size biotechnology company.

ADCs will be evaluated by the Company's collaborators based on different Syntarga proprietary Linker-Drug chemistries and a variety of collaborator antibodies. Syntarga has generated a strong biological data package for its synthetic Linker-Drug payloads with ADCs against multiple antigen targets, including Her2. The Company believes that more research collaborations with established companies will be started in the near future.

"The steadily increasing number of collaborations with top-tier biopharma companies exemplify the growing interest in Syntarga’s proprietary Linker-Drug technology to empower anticancer antibodies. These relationships help the Company with implementing its strategy to bring ADC products based on its technology into the clinic as soon as feasible." said Dr. Vincent de Groot, Chief Executive Officer of Syntarga.

About Syntarga BV

Syntarga is a privately held biopharmaceutical company engaged in the discovery and development of proprietary Antibody-Drug Conjugate technology and products for the treatment of cancer. The Company's cutting-edge chemistry capabilities and unique know-how have led to the creation of its antibody empowering Potent Payload Technology. Syntarga is leveraging its proprietary technologies and expertise to generate and commercialize, alone and with partners, a portfolio of next generation Antibody-Drug Conjugate products. For more information about Syntarga, visit its website at www.syntarga.com.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES